Remove tag patient-adherence
article thumbnail

BD partners with Biocorp on connected self-injection devices

pharmaphorum

Medtech giant Beckton Dickinson (BD) has signed a deal with France’s Biocorp to use the latter’s near-field communication (NFC) tags in injectable devices. The Injay tag can confirm a complete injection and transfer that information via an NFC reader to a smartphone or tablet for review by a healthcare professional.

article thumbnail

Patient adherence – the key to restoring trust in pharma

pharmaphorum

This lack of trust in such a crucial industry can lead to decreased compliance, poor treatment adherence, and negative health outcomes for patients. Additionally, when patients are prescribed medication, they are often unaware of the mechanism of action, potential side effects, interactions, and contraindications.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Mastering the Art of Presentation: Choosing the Perfect Sample Bag for Pharma Sales Success

Contrarian Sales Techniques

Personalize with Name Tags or Initials: A Personal Touch Adding a name tag or your initials can give your sample bag a personal touch. Patient Safety and Product Integrity A key ethical concern in the distribution of pharmaceutical samples is patient safety.

Sales 52
article thumbnail

How to Optimize Your Website for Google’s Helpful Content Update

Healthcare Success

If you are an existing client, please know our content creation process has always adhered to Google’s quality guidelines, and we only implement white-hat, ethical SEO practices.]. This allows us to be more authentic when writing valuable, helpful content that meets their needs, the needs of their patients, and Google’s content requirements.

article thumbnail

Don’t Wait—Uncover the Clinical Endpoints that Will Matter to Payers and HCPs

PM360

Simply getting a patient into a physician’s practice doesn’t guarantee that a product will be utilized or paid for by health plans or self-insured companies. This option grows more critical as new therapies become available with price tags as high as $3.5 million for the new hemophilia gene therapy.